Sucampo Pharma (SCMP) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls on weaker demand outlook and higher US stocks
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
UPDATE: Cantor Fitzgerald Downgrades Sucampo Pharmaceuticals (SCMP) to Hold
May 7, 2015 6:59 AM EDT(Updated - May 7, 2015 9:24 AM EDT)
Cantor Fitzgerald downgraded Sucampo Pharmaceuticals (NASDAQ: SCMP) from Buy to Hold. Comments follow mixed Q1 results. Analyst Irina Rivkind Koffler views shares as fully valued and thinks the stock will trade range-bound.
"Sucampo reported revenues of $29.5... More
